Clinical Trial Update: Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL [Phase 2]

View source ↗

Summary

This trial update reports Phase 2 results for a triple regimen of acalabrutinib, lenalidomide, and rituximab in patients with untreated Mantle Cell Lymphoma. Re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-06